PlainRecalls
LowClass IIITerminated

FDA Drug recall · Reported September 5, 2012

Bracco Diagnostics multihance (gadobenate dimeglumine) injection, 529 mg/mL, 20ml, Rx only, Manufactured for: Bracco Diagnostics Inc., Princeton, NJ 08543 USA, NDC 0270-5164-15

Short Fill: The product is being recalled due to a potential underfill of the affected vials.

Recall #
D-1663-2012
Affected scope
47,750 vials
Initiated
April 16, 2012
Verify with FDA Drug →
View my saved recalls

Bracco Diagnostics Inc recalled Bracco Diagnostics multihance (gadobenate dimeglumine) injection, 529 mg/mL, 20ml, Rx onl… - a low-severity action.

Bracco Diagnostics multihance (gadobenate dimeglumine) injection, 529 mg/mL, 20ml, Rx onl… was recalled by Bracco Diagnostics Inc in September 5, 2012. Reason: Short Fill: The product is being recalled due to a potential underfill of the affected vials.. Check the official notice for the remedy. Verify recall #D-1663-2012 with the FDA Drug before acting.

The recall

Bracco Diagnostics Inc issued this low-severity FDA Drug recall-Short Fill: The product is being recalled due to a potential underfill of the affected vials..

Low
severity level
Class III
classification
September 5, 2012
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-1663-2012 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This FDA Drug action (record #D-1663-2012) was formally reported on September 5, 2012, with the manufacturer initiating the action on April 16, 2012. It is classified under Low severity (Class III), with a current status of Terminated. Bracco Diagnostics Inc is listed as the recalling firm, operating out of Monroe Township, NJ. Federal records list the affected scope as 47,750 vials.

The documented reason for this recall is: Short Fill: The product is being recalled due to a potential underfill of the affected vials. Distribution data in the federal record shows the product reached: Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Drugs & Medications recalls over time

Where this recall sits in its category - 14,287 drugs & medications recalls on record

-50005001,0001,5002,000 2006201220152018202120242026 263
Severity2487872426High severity (most serious)Moderate severityLow severity
Where this recall sits in the database

Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Severity

Low

Affected scope

47,750 vials

Related Recalls

6

5 from same agency

Product description

Bracco Diagnostics multihance (gadobenate dimeglumine) injection, 529 mg/mL, 20ml, Rx only, Manufactured for: Bracco Diagnostics Inc., Princeton, NJ 08543 USA, NDC 0270-5164-15

Reason for recall

Short Fill: The product is being recalled due to a potential underfill of the affected vials.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute Value
Agency U.S. Food and Drug Administration
Severity class Low (Class III)
Status Terminated
Recall number D-1663-2012
Date reported September 5, 2012
Date initiated April 16, 2012
Recalling firm Bracco Diagnostics Inc
Firm location Monroe Township, NJ
Affected scope 47,750 vials
Distribution Nationwide

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

  • Check the recall number (D-1663-2012) and product description against the item you own. Search the archive
  • Confirm the current status with FDA Drug before acting, recall details can be updated.
  • Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
Bracco Diagnostics multihance (gadobenate dimeglumine) injection, 529 mg/mL, 20ml, Rx only, Manufactured for: Bracco Diagnostics Inc., Princeton, NJ 08543 USA, NDC 0270-5164-15. Recalled by Bracco Diagnostics Inc. Units affected: 47,750 vials.
Why was this product recalled?
Short Fill: The product is being recalled due to a potential underfill of the affected vials.
Which agency issued this recall?
This recall was issued by the FDA Drug on September 5, 2012. Severity: Low. Recall number: D-1663-2012.
Where was the recalled product distributed?
Distribution: Nationwide.
How do I check if my product is affected by a recall?
Check the product description and recall number (D-1663-2012) against your product. Visit the official FDA Drug website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
Should I stop using a recalled medication or medical device?
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nearby Recalls in This Category

Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.

Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →

Browse all Drugs & Medications recalls →

Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported September 5, 2012. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.